Private Advisor Group’s Cardiff Oncology CRDF Stock Holding History

Private Advisor Group’s Portfolio CRDF Stock Details CRDF Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-9	Closed	–	–	1925
2020 Q2	$0	Buy	+9	New	+$18	﹤0.01%	3848

Other funds holding CRDF

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Corriente Advisors Fort Worth, Texas $9.53M AUM 805.26% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Private Advisor Group's CRDF Position: Q3 2020 in Review

Private Advisor Group sold out of Cardiff Oncology (CRDF) in Q3 2020, closing a stake of 9 shares.

Private Advisor Group first reported a position in CRDF in Q2 2020 and held it in 1 quarter. The position peaked at $0 in Q2 2020. 67 funds tracked by Wall St. Rank hold CRDF as of Q3 2020.

Private Advisor Group reported no remaining Cardiff Oncology position as of Q3 2020 after selling out during the quarter.
Private Advisor Group sold 9 Cardiff Oncology shares in Q3 2020.
Private Advisor Group first reported a position in Cardiff Oncology in Q2 2020 and held it in 1 quarter.
Private Advisor Group's Cardiff Oncology position peaked at $0 in Q2 2020.
67 funds tracked by Wall St. Rank held Cardiff Oncology as of Q3 2020.

Based on Private Advisor Group's 13F filing for Q3 2020, filed 2 Nov 2020.